Docusate/Senna for the Treatment of Diabetic Gastroparesis
Status:
Terminated
Trial end date:
2018-08-17
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy of the stimulant laxative Senokot-S® for the
treatment of diabetic gastroparesis. Senokot-S, and its metabolites, are thought to produce
peristalsis, drive intraluminal fluid and electrolyte shifts, and have an irritant effect on
the gut mucosa. These complex physiologic mechanisms appear may sufficiently promote stomach
emp-tying, and thereby reduce or eliminate the severity of gastroparesis symptoms. In this
open label study, participants will be randomized into high and low dose groups to assess for
ideal dosing and tolerability. It is the overall goal of this study to select the most
promising dose-strength for the treatment of mild through severe gastroparesis.